Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Heidelberger Druckmaschinen in connection with the acquisition of Fujifilm Sverige
Mandate

Vinge advises Heidelberger Druckmaschinen in connection with the acquisition of Fujifilm Sverige

March 30, 2015

Vinge advises Heidelberger Druckmaschinen AG in connection with the acquisition of Fujifilm Sverige AB from Axel Johnson International AB. Heidelberger Druckmaschinen is a leading global manufacturer of offset printing presses with head offices in Heidelberg. Through this acquisition, Heidelberger Druckmaschinen is significantly expanding its service and consumables business in Sweden and gives the company a strong position in this market.

Vinge’s team consists of responsible partner Jonas Bergström together with Matthias Pannier (both corporate).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024